Partnering with us

Akston is building deep partnerships around the world. We license our patents for commercialization and maintain close involvement with our partners throughout the development process.

We have licensed our two once-a-week veterinary insulins to Dechra Pharmaceutical PLC and our COVID-19 vaccine to Biolexis, a Strides Group Company. We have partnered with the Helmsley Charitable Trust to develop our Human type 1 diabetes intervention. Our company also has active development programs in human once-a-week insulin and oncology.

If you are interested in speaking with us about partnering opportunities, please contact us.

 


Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Additional information is available at www.dechra.com

 

 


Helmsley Charitable Trust aspires to improve lives by supporting effective organizations in health, place-based initiatives, education and human services. Since beginning active grantmaking in 2008, Helmsley has committed more than $1.8 billion for a wide range of charitable purposes. Additional information is available at www.helmsleytrust.org

 

 



Strides develops and manufacture sof wide range of niche and technically complex pharmaceutical products. We are also among the world’s largest soft gelatin capsule manufacturers. Additional information is available at www.strides.com.

 


Additional information is available at www.stelis.com   and at www.biolexistx.com

 

 


NIDDK  research creates knowledge about and treatments for diseases that are among the most chronic, costly, and consequential for patients, their families, and the Nation. Additional information is available at www.niddk.nih.gov